94
Views
4
CrossRef citations to date
0
Altmetric
Article

Characteristics of patients with liver disease intravenously exposed to diethylene glycol in China 2006

, , , &
Pages 124-131 | Received 13 Apr 2008, Accepted 03 Jun 2008, Published online: 01 Feb 2009
 

Abstract

Background. Diethylene glycol (DEG) poisoning is life-threatening. The clinical characteristics of patients with liver disease exposed to intravenous DEG have not been clarified. Methods. Sixty-four patients with moderate to severe liver disease exposed to DEG in China in 2006 were investigated. Results. The daily exposure total dose was 3–6 mL of a 30% (v/v) mixture. Acute renal failure (ARF), the predominant clinical manifestation, occurred in 23.4% (15/64) of these patients. The average time to onset was 6.53 ± 3.48 days after exposure to DEG. ARF could be differentiated from the hepatorenal syndrome that usually occurs in patients with severe liver disease. The occurrence of ARF was significantly related to pre-existing renal function abnormality, and was not influenced by the allele distribution of DEG-metabolizing enzyme. The liver function profiles did not significantly change after DEG exposure. Conclusions. ARF was the main clinical manifestation in this intravenous DEG poisoning accident. The influence of underlying liver disease on DEG poisoning or that of DEG exposure on liver disease has many implications.

Acknowledgments

We thank the staff of the Liver Disease Key Laboratory and the Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.